RNXT - RenovoRx Inc

RNXT - RenovoRx Inc

https://renovorx.com

Recent News

Powered by Alpha Vantage

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th - RenovoRx ( NASDAQ:RNXT )

Benzinga • 4 days, 3 hours ago • score: 0.14

MOUNTAIN VIEW, Calif., Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- RenovoRx, Inc. ( "RenovoRx" or the "Company" ) RNXT, a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun ...

RenovoRx Revenue Jumps 28 Percent in Q2

Motley Fool • 1 month ago • score: 0.16

RenovoRx ( NASDAQ:RNXT ) , a medical technology company focused on targeted cancer therapy delivery, reported earnings on August 14, 2025. As sales of its RenovoCath device grew to $422,000 ( GAAP ) , surpassing the analyst consensus of $329,633 ( GAAP ) by 28.0%.

RenovoRx, Inc. ( RNXT ) Reports Q2 Loss, Tops Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.11

RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and +22.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire - RenovoRx ( NASDAQ:RNXT )

Benzinga • 1 month, 1 week ago • score: 0.19

RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat orders of RenovoCath for interventional radiology procedures

RenovoRx, Inc. ( RNXT ) Reports Q1 Loss, Lags Revenue Estimates

Zacks Commentary • 3 months, 4 weeks ago • score: 0.16

RenovoRx (RNXT) delivered earnings and revenue surprises of 0% and 1.50%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. The company is headquartered in Los Altos, California.

52W High

$1.69

52W Low

$0.75

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.23

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-4.72

EV/Revenue (<3 favorable)

50.43

P/S (TTM) (<3 favorable)

68.64

P/B (<3 favorable)

4.27

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

4.44%

Institutions (25–75% balanced)

24.00%

Shares Outstanding

36,645,900

Float

30,083,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

662,000

Gross Profit (TTM)

416,000

EPS (TTM)

-0.38

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-6.35%

ROE (TTM) (>15% strong)

-1.07%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—